epidermolysis bullosa

Showing 2 posts of 2 posts found.


Promising interim Phase 3 data spurs epidermolysis bullosa trial expansion for Amryt

January 7, 2019
Research and Development, Sales and Marketing Amryt, epidermolysis bullosa, pharma, rare disease

Rare disease firm Amryt has announced interim efficacy data for its epidermolysis bullosa (EB) therapy AP101, showing that things are …


Amicus pulls plug on rare skin disease drug after Phase 3 failure

September 14, 2017
Research and Development Amicus, epidermolysis bullosa, pharma, pharmaceutical, trial failure

New Jersey-based biotech firm Amicus Therapeutics has been forced to terminate its development of its candidate for treating rare skin …

Latest content